ArticleBMC surgery2025
BMP-2 gene-modified mesenchymal stem cells enhance tendon-bone healing in ACL reconstruction: a rabbit micro-CT and biomechanical study.
Article in BMC surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveSuboptimal tendon-bone interface healing remains a critical challenge affecting outcomes of anterior cruciate ligament (ACL) reconstruction. This study investigates whether BMP-2 gene-modified bone marrow mesenchymal stem cells (MSCs) enhances tendon-bone osseointegration.
methodsAn ACL reconstruction model was established in 18 New Zealand white rabbits, randomized into three groups: Control(fibrin glue), MSCs-Ad (adenovirus-vector transfected MSCs), MSCs-BMP2 (BMP-2-overexpressing MSCs). Micro-CT analysis and biomechanical testing assessed bone regeneration and interface properties at 4 weeks postoperatively.
resultsMicro-CT analysis revealed a significant enhancement in bone regeneration within the tunnel in the order of MSCs-BMP2 > MSCs-Ad > Control. The MSCs-BMP2 group demonstrated the highest values for bone volume fraction (BV/TV: 0.35 ± 0.05 vs. 0.27 ± 0.03 in MSCs-Ad vs. 0.22 ± 0.03 in Control), trabecular number (Tb.N: 0.73 ± 0.01 vs. 0.68 ± 0.01 vs. 0.64 ± 0.03), and trabecular thickness (Tb.Th: 0.46 ± 0.02 vs. 0.38 ± 0.01 vs. 0.36 ± 0.03). Biomechanical testing yielded consistent results: the maximum failure load for the MSCs-BMP2 group (32.80 ± 3.94 N) was significantly greater than that of both the MSCs-Ad (27.37 ± 2.15 N) and control (21.07 ± 1.94 N) groups, while the MSCs-Ad group also showed a significant improvement over the control.
conclusionBMP-2 gene-modified MSCs synergistically accelerate tendon-bone osseointegration, providing a theoretical foundation for biological augmentation in ACL reconstruction. This strategy may reduce postoperative graft failure risks. Future studies should validate clinical translation through long-term monitoring and mechanistic investigations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.